{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:01:06Z","timestamp":1793127666645,"version":"4.5.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"Importance<\/jats:title>Large-scale genome-wide association studies (GWAS) should ideally inform the development of pharmacological treatments, but whether GWAS-identified mechanisms of disease liability correspond to the pathophysiological processes targeted by current pharmacological treatments is unclear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate whether functional information from a range of open bioinformatics datasets can elucidate the relationship between GWAS-identified genetic variation and the genes targeted by current treatments for psychiatric disorders.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Associations between GWAS-identified genetic variation and pharmacological treatment targets were investigated across 4 psychiatric disorders\u2014attention-deficit\/hyperactivity disorder, bipolar disorder, schizophrenia, and major depressive disorder. Using a candidate set of 2232 genes listed as targets for all approved treatments in the DrugBank database, each gene was independently assigned 2 scores for each disorder\u2014one based on its involvement as a treatment target and the other based on the mapping between GWAS-implicated single-nucleotide variants (SNVs) and genes according to 1 of 4 bioinformatic data modalities: SNV position, gene distance on the protein-protein interaction (PPI) network, brain expression quantitative trail locus (eQTL), and gene expression patterns across the brain. Study data were analyzed from November 2023 to September 2024.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Gene scores for pharmacological treatments and GWAS-implicated genes were compared using a measure of weighted similarity applying a stringent null hypothesis\u2013testing framework that quantified the specificity of the match by comparing identified associations for a particular disorder with a randomly selected set of treatments.<\/jats:p><\/jats:sec>Results<\/jats:title>Incorporating information derived from functional bioinformatics data in the form of a PPI network revealed links for bipolar disorder (P<\/jats:italic> permutation [P<\/jats:italic>-perm]\u2009=\u20097\u2009\u00d7\u200910\u22124<\/jats:sup>; weighted similarity score, empirical [\u03c1-emp] = 0.1347; mean [SD] weighted similarity score, random [\u03c1-rand] = 0.0704 [0.0163]); however, the overall correspondence between treatment targets and GWAS-implicated genes in psychiatric disorders rarely exceeded null expectations. Exploratory analysis assessing the overlap between the GWAS-identified genetic architecture and treatment targets across disorders identified that most disorder pairs and mapping methods did not show a significant correspondence.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this bioinformatic study, the relatively low degree of correspondence across modalities suggests that the genetic architecture driving the risk for psychiatric disorders may be distinct from the pathophysiological mechanisms currently used for targeting symptom manifestations through pharmacological treatments. Novel approaches incorporating insights derived from GWAS based on refined phenotypes including treatment response may assist in mapping disorder risk genes to pharmacological treatments in the long term.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2024.3846","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:29:58Z","timestamp":1733948998000},"page":"151","source":"Crossref","is-referenced-by-count":12,"title":["Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders"],"prefix":"10.1001","volume":"82","author":[{"given":"Aurina","family":"Arnatkeviciute","sequence":"first","affiliation":[{"name":"The Turner Institute for Brain and Mental Health, School of Psychological Sciences, and Monash Biomedical Imaging, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Fornito","sequence":"additional","affiliation":[{"name":"The Turner Institute for Brain and Mental Health, School of Psychological Sciences, and Monash Biomedical Imaging, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Tong","sequence":"additional","affiliation":[{"name":"The Turner Institute for Brain and Mental Health, School of Psychological Sciences, and Monash Biomedical Imaging, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Pang","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, Royal Children\u2019s Hospital, Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben D.","family":"Fulcher","sequence":"additional","affiliation":[{"name":"School of Physics, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Bellgrove","sequence":"additional","affiliation":[{"name":"The Turner Institute for Brain and Mental Health, School of Psychological Sciences, and Monash Biomedical Imaging, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"yoi240076r1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002822","article-title":"Chapter 11: genome-wide association studies.","volume":"8","author":"Bush","year":"2012","journal-title":"PLOS Comput Biol"},{"key":"yoi240076r2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4088\/JCP.v67n0502","article-title":"Mechanism of action of agents used in attention-deficit\/hyperactivity disorder.","volume":"67","author":"Wilens","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi240076r3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cellsig.2004.12.007","article-title":"Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways.","volume":"17","author":"Taylor","year":"2005","journal-title":"Cell Signal"},{"issue":"1","key":"yoi240076r4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"issue":"5","key":"yoi240076r5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41588-018-0090-3","article-title":"Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.","volume":"50","author":"Wray","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"yoi240076r6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41588-018-0269-7","article-title":"Discovery of the first genome-wide significant risk loci for attention deficit\/hyperactivity disorder.","volume":"51","author":"Demontis","year":"2019","journal-title":"Nat Genet"},{"issue":"7510","key":"yoi240076r7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci.","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature"},{"issue":"10128","key":"yoi240076r8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"yoi240076r9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"10202","key":"yoi240076r10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multiepisode schizophrenia: a systematic review and network meta-analysis.","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"yoi240076r11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/DHPS.S37429","article-title":"Antipsychotic agents: efficacy and safety in schizophrenia.","volume":"4","author":"de Ara\u00fajo","year":"2012","journal-title":"Drug Healthc Patient Saf"},{"issue":"3","key":"yoi240076r12","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.472","article-title":"Depressive disorders: treatment failures and poor prognosis over the last 50 years.","volume":"7","author":"Blackburn","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"10","key":"yoi240076r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2022.100190","article-title":"A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis.","volume":"2","author":"Namba","year":"2022","journal-title":"Cell Genom"},{"issue":"10","key":"yoi240076r14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41576-021-00387-z","article-title":"Advancing the use of genome-wide association studies for drug repurposing.","volume":"22","author":"Reay","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"7","key":"yoi240076r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2023.100341","article-title":"Multilayered genetic approaches to identify approved drug targets.","volume":"3","author":"Sadler","year":"2023","journal-title":"Cell Genom"},{"issue":"8","key":"yoi240076r16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications.","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"yoi240076r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008489","article-title":"Are drug targets with genetic support twice as likely to be approved\u2014revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.","volume":"15","author":"King","year":"2019","journal-title":"PLoS Genet"},{"issue":"4","key":"yoi240076r18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nbt.2151","article-title":"Use of genome-wide association studies for drug repositioning.","volume":"30","author":"Sanseau","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"1","key":"yoi240076r19","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1038\/s41598-017-12325-3","article-title":"Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach.","volume":"7","author":"Gaspar","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"yoi240076r20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2215-0366(15)00553-2","article-title":"Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.","volume":"3","author":"Ruderfer","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"16","key":"yoi240076r21","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1017\/S0033291718003641","article-title":"Translating GWAS findings into therapies for depression and anxiety disorders: gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning.","volume":"49","author":"So","year":"2019","journal-title":"Psychol Med"},{"issue":"4","key":"yoi240076r22","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1471-2164-15-S4-S5","article-title":"GWAS and drug targets.","volume":"15","author":"Cao","year":"2014","journal-title":"BMC Genomics"},{"issue":"383","key":"yoi240076r23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1166","article-title":"The druggable genome and support for target identification and validation in drug development.","volume":"9","author":"Finan","year":"2017","journal-title":"Sci Transl Med"},{"issue":"11","key":"yoi240076r24","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/nn.4409","article-title":"The road to precision psychiatry: translating genetics into disease mechanisms.","volume":"19","author":"Gandal","year":"2016","journal-title":"Nat Neurosci"},{"key":"yoi240076r25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ebiom.2018.01.015","article-title":"Disconnect between genes associated with ischemic heart disease and targets of ischemic heart disease treatments.","volume":"28","author":"Schooling","year":"2018","journal-title":"EBioMedicine"},{"issue":"7","key":"yoi240076r26","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/mp.2015.28","article-title":"Targeting the schizophrenia genome: a fast-track strategy from GWAS to clinic.","volume":"20","author":"Lencz","year":"2015","journal-title":"Mol Psychiatry"},{"issue":"6","key":"yoi240076r27","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.drudis.2019.03.024","article-title":"Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities.","volume":"24","author":"Jhamb","year":"2019","journal-title":"Drug Discov Today"},{"issue":"1","key":"yoi240076r28","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S2665-9913(19)30134-1","article-title":"From genome-wide association studies to rational drug target prioritization in inflammatory arthritis.","volume":"2","author":"Fang","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"yoi240076r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102206","article-title":"Network analysis of genome-wide association studies for drug target prioritisation.","volume":"71","author":"Barrio-Hernandez","year":"2022","journal-title":"Curr Opin Chem Biol"},{"issue":"D1","key":"yoi240076r30","doi-asserted-by":"publisher","first-page":"D972","DOI":"10.1093\/nar\/gkad832","article-title":"PharmGWAS: a GWAS-based knowledgebase for drug repurposing.","volume":"52","author":"Kang","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"yoi240076r31","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41588-019-0456-1","article-title":"A genetics-led approach defines the drug target landscape of 30 immune-related traits.","volume":"51","author":"Fang","year":"2019","journal-title":"Nat Genet"},{"issue":"10","key":"yoi240076r32","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/nn.4618","article-title":"Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry.","volume":"20","author":"So","year":"2017","journal-title":"Nat Neurosci"},{"issue":"1","key":"yoi240076r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1009224","article-title":"Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome.","volume":"17","author":"Baird","year":"2021","journal-title":"PLoS Genet"},{"issue":"2","key":"yoi240076r34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41386-022-01456-5","article-title":"Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.","volume":"48","author":"Liu","year":"2023","journal-title":"Neuropsychopharmacol"},{"issue":"5","key":"yoi240076r35","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/schbul\/sbad100","article-title":"Mendelian randomization using the druggable genome reveals genetically supported drug targets for psychiatric disorders.","volume":"49","author":"Li","year":"2023","journal-title":"Schizophr Bull"},{"issue":"9922","key":"yoi240076r36","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"issue":"Database issue","key":"yoi240076r37","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration.","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"issue":"7416","key":"yoi240076r38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature11405","article-title":"An anatomically comprehensive atlas of the adult human brain transcriptome.","volume":"489","author":"Hawrylycz","year":"2012","journal-title":"Nature"},{"issue":"7488","key":"yoi240076r39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery.","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"issue":"9","key":"yoi240076r40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/ng.2711","article-title":"Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs.","volume":"45","author":"Lee","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"yoi240076r41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","article-title":"Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions.","volume":"22","author":"Howard","year":"2019","journal-title":"Nat Neurosci"},{"issue":"7","key":"yoi240076r42","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.cell.2018.05.046","article-title":"Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes.","volume":"173","author":"Ruderfer","year":"2018","journal-title":"Cell"},{"issue":"1","key":"yoi240076r43","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1038\/s41467-018-04951-w","article-title":"Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.","volume":"9","author":"Xue","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"yoi240076r44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-022-01285-8","article-title":"Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture, and implicate several cognitive domains.","volume":"55","author":"Demontis","year":"2023","journal-title":"Nat Genet"},{"issue":"7906","key":"yoi240076r45","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia.","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"issue":"5","key":"yoi240076r46","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41588-019-0397-8","article-title":"Genome-wide association study identifies 30 loci associated with bipolar disorder.","volume":"51","author":"Stahl","year":"2019","journal-title":"Nat Genet"},{"issue":"7","key":"yoi240076r47","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41591-023-02352-1","article-title":"Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses.","volume":"29","author":"Als","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"yoi240076r48","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/wps.20870","article-title":"Explaining the missing heritability of psychiatric disorders.","volume":"20","author":"Owen","year":"2021","journal-title":"World Psychiatry"},{"issue":"1","key":"yoi240076r49","doi-asserted-by":"publisher","first-page":"10531","DOI":"10.1038\/ncomms10531","article-title":"Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes.","volume":"7","author":"Imamura","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"yoi240076r50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nn.3922","article-title":"Psychiatric genome-wide association study analyses implicate neuronal, immune, and histone pathways.","volume":"18","author":"O\u2019Dushlaine","year":"2015","journal-title":"Nat Neurosci"},{"issue":"8","key":"yoi240076r51","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1177\/0269881116653109","article-title":"Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.","volume":"30","author":"de Jong","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"1","key":"yoi240076r52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13072-015-0050-4","article-title":"Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in noncoding regions of the human genome.","volume":"8","author":"Tak","year":"2015","journal-title":"Epigenetics Chromatin"},{"issue":"4","key":"yoi240076r53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004219","article-title":"MAGMA: generalized gene-set analysis of GWAS data.","volume":"11","author":"de Leeuw","year":"2015","journal-title":"PLOS Comput Biol"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2827732\/jamapsychiatry_arnatkeviciute_2024_oi_240076_1738174972.42674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T16:01:20Z","timestamp":1738771280000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2827732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.3846","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}